This review provides a comprehensive overview of the intricate mechanisms of this enzyme and evaluates the existing evidence regarding the therapeutic potential of GSK-3β in brain diseases, including Alzheimer’s disease, Parkinson’s disease, mood disorders, and glioblastoma. This evidence concerns the gene GSK3B and early-onset autosomal dominant Alzheimer disease.